Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 294-297

  Prat, Aleix ^a   Parera, M ^a   Adamo, B ^a   Peralta, S ^a   Perez Benavente, M A ^a   Garcia, A ^a   Gil Moreno, A ^a   Martinez Palones, J M ^a   Baselga, J ^a   del Campo, J M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

CA 125; Ovarian cancer; Recurrence; Residual disease, surveillance

Indexed keywords

CA 125 ANTIGEN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 60549093588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn601     Document Type: Article

References (16)

1. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360: 505-515.
2. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
3. Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18: 881-885.
4. Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: Results of a French multicentric study. Ann Oncol 2006; 17: 1234-1238.
5. van der Burg MEL, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301-302.
6. Vergote I, Rustin GJS, Eisenhauer EA et al. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst 2000; 92: 1534-1535.
7. Crawford SM, Paul J, Reed NS et al. The prognostic significance of the CA125 nadir in patients that achieve a CA125 response. Proc Am Soc Clin Oncol 2004; 23: 448 Abstr 5001.
8. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005; 16: 47-50.
9. Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24: 1454-1458.
10. Juretzka MM, Barakat RR, Chi DS et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007; 104: 176-180.
11. Prat A, Parera M, Peralta S et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 2007.
12. Santillan A, Garg R, Zahurak ML et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-9343.
13. Liu P-Y, Alberts DS, Monk BJ et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007; 25: 3615-3620.
14. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol 2003; 21: 2460-2465.
15. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study. Ann Oncol 1996; 7: 361-364.
16. Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8: 813-821.